CSPC Pharmaceutical Group company profile
Company profile
CSPC Pharmaceutical Group has 18,626 employees and is headquartered in Shijiazhuang, China.
CSPC Pharmaceutical Group serves patients and healthcare providers in Mainland China, other Asian regions, Europe, North America and other international markets, manufacturing and selling finished drugs, bulk products and functional food items. Its portfolio covers stroke, memory impairment, Parkinson's disease, cancer and chemotherapy-related infection support, antibiotics, hypertension, diabetes, osteoporosis, arthritis and pain relief, as well as active pharmaceutical ingredients such as antibiotics, vitamin C and caffeine. The company also provides healthcare services and has a strategic collaboration with AstraZeneca PLC on novel oral candidates for obesity and type 2 diabetes.
In the fiscal year ended December 2025, revenue was 26.0 billion yuan, down 10.4% from the previous year, and net profit was 3.9 billion yuan. The company employed 18,626 people. It was incorporated in 1992, formerly known as China Pharmaceutical Group Limited until its name change in March 2013, and is headquartered in Shijiazhuang, China.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Hong Kong SAR China
- Headquarters
- No.896 Zhongshandong Street, 050035, Shijiazhuang
- Employees
- 18,626
- Chief executive
- Lei Cai
- Founded
- 1992
- Fiscal year
- January - December
- Listing
- 1093 · HKEX
- Indices
- Hang Seng
- Currency
- HKD
- ISIN
- HK1093012172
- Website
- cspc.com.hk
CSPC Pharmaceutical Group and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| CSPC Pharmaceutical Group1093 | Hong Kong SAR China | $11.47B | 18,626 | 27.9% | 10.8 |
| Astellas Pharma4503 | Japan | $30.89B | 14,099 | 23.5% | 12.8 |
| Daiichi Sankyo4568 | Japan | $32.83B | 20,171 | 12.6% | 18.8 |
| Otsuka Holdings4578 | Japan | $41.01B | 37,758 | 18.0% | 17.0 |
| Chugai Pharmaceutical4519 | Japan | $76.25B | 5,104 | 48.3% | 24.1 |
| RecordatiREC | Italy | $12.09B | 4,700 | 32.6% | 21.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
